In order to more thoroughly evaluate the impact of GGPPS inhibition in AML, a small group of AML cell lines with wild-type (e.g. MOLM-13), or a mutated (e.g. NOMO-1, Kasumi-1 and THP-1,) TP53 genes were tested using GGPPS inhibitors CML-07–119 or cytarabine. The gene discussed is GGPS1; the disease is acute myeloid leukemia.